Pharmaceuticals

OCT 23, 2026 · JOURNAL ARTICLE

Preclinical Evaluation of 177Lu-Labeled PSMA and FAP Bispecific Radioligand for Prostate Cancer

Pharmaceuticals

Background/Objectives: During prostate cancer progression, downregulation or loss of prostate-specific membrane antigen (PSMA) expression, together with interlesional heterogeneity

OCT 20, 2026 · JOURNAL ARTICLE

From Design to Synergy: Triazine–Triazole Hybrids as Anti-Breast Cancer Leads Targeting Survival and Invasion Pathways for Augmenting Lapatinib Efficacy

Pharmaceuticals

Background/Objectives: Breast cancer is the most common cancer diagnosed and the leading cause of cancer-related deaths among women, ranking fourth overall in both sexes. Its treat

OCT 14, 2026 · JOURNAL ARTICLE

Targeting PAK1 Within Group I PAKs: Current Challenges and Pharmacological Perspectives

Pharmaceuticals

The p21-activated kinase 1 (PAK1) has been investigated as a therapeutic target for more than two decades, particularly in cancer, where it contributes to cytoskeletal regulation,

OCT 13, 2026 · JOURNAL ARTICLE

Neurotensin-Based Radioligands for NTS1R-Targeted Cancer Theranostics: Background, Current Status and Future Trends

Pharmaceuticals

Background/Objectives: The neurotensin subtype-1 receptor (NTS1R) is overexpressed in a number of human tumors, representing a valid biomolecular target for neurotensin-based radio

OCT 12, 2026 · JOURNAL ARTICLE

Virological Events During Immune Checkpoint Inhibitor Therapy: A Multi-Source Evaluation

Pharmaceuticals

Background/Objectives: Virological findings during immune checkpoint inhibitor (ICI) therapy may represent viral loss of control, pre-existing infection, tumour biomarkers, or infe

OCT 9, 2026 · JOURNAL ARTICLE

Selenium Nanoparticles Functionalized with Tumor-Targeting Peptides for Lung Cancer Therapy: A Comprehensive Review

Pharmaceuticals

Lung cancer is among the most fatal malignancies worldwide, with approximately 85% of diagnosed cases being non-small-cell lung cancer (NSCLC). Despite the considerable progress in

OCT 7, 2026 · JOURNAL ARTICLE

Context-Dependent Modulation of Lipolytic Activity by Ginkgo biloba Extract: Evidence from Murine and Human Adipose Models

Pharmaceuticals

Background/Objectives: Dysregulated lipolysis contributes to adipose tissue dysfunction in obesity. Ginkgo biloba extract (GbE) influences adipose metabolism, but its effects acros

OCT 1, 2026 · JOURNAL ARTICLE

Mechanisms and Therapeutic Advances of Natural Products Regulating Non-Coding RNAs in Cancer

Pharmaceuticals

Non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, circular RNAs, tRNA-derived fragments, PIWI-interacting RNAs, and small nucleolar RNAs, have been identified as